EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial Meeting Abstract

  

Authors:	Miller, V. A.; Zakowski, M.; Riely, G. J.; Pao, W.; Ladanyi, M.; Tsao, A. S.; Sandler, A.; Herbst, R.; Kris, M. G.; Johnson, D. H.
Abstract Title:	EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial
Meeting Title:	42nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	24
Issue:	18 Suppl. Pt. 1
Meeting Dates:	2006 Jun 2-6
Meeting Location:	Atlanta, GA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2006-06-01
Start Page:	364S
Language:	English
ACCESSION:	WOS:000239009402328
PROVIDER:	wos
DOI:	10.1200/jco.2006.24.18_suppl.7003
Notes:	--- - Meeting Abstract: 7003 - 42nd Annual Meeting of the American-Society-of-Clinical-Oncology - JUN 02-06, 2006 - Atlanta, GA - S - Part 1 - "Source: Wos"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/32428